NCT00070707

Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)

Efficacy and Safety of Nasonex vs. Placebo in Subjects With SAR and Concomitant Asthma

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 188 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 15 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study will compare mometasone nasal spray to placebo in treating the nasal and asthma symptoms experienced by participants with seasonal allergic rhinitis (SAR) and concomitant asthma.

Conditions

• Rhinitis, Allergic, Seasonal
• Asthma

Interventions

Type	Name	Description
DRUG	Mometasone	Mometasone nasal spray 200 mcg/day administered as 2 sprays (50 mcg/spray) in each nostril.
DRUG	Placebo	Matching placebo nasal spray, administered QD as 2 sprays in each nostril.
DRUG	Albuterol/Salbutamol	Albuterol/salbutamol metered dose inhaler (90 mcg/puff) used as needed as asthma rescue medication.

Timeline

• Start date: 2003-04-03
• Primary completion: 2003-11-26
• Completion: 2003-11-26
• First posted: 2003-10-10
• Last updated: 2024-09-05
• Results posted: 2019-07-18

Regulatory

• FDA-regulated drug study